Tech Company Financing Transactions
Allievex Funding Round
Allievex, based in Marblehead, secured investment capital from Novo Ventures, Pappas Ventures and private investors.
Transaction Overview
Company Name
Announced On
10/24/2019
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Investors
Novo Ventures (Lead Investor) (Tiba Aynechi)
Pappas Ventures (Lead Investor) (Thomas Mathers)
Proceeds Purpose
Proceeds from the fundraise will be used to support registrational Phase 2 clinical studies of Allievex's lead product candidate, tralesinidase alfa (formerly known as BMN 250), an investigational enzyme replacement therapy to treat Sanfilippo syndrome type B or mucopolysaccharidosis IIIB (MPS IIIB) for which Allievex has obtained an exclusive, worldwide license from BioMarin Pharmaceutical Inc. Under the terms of its agreement with BioMarin.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
P.O. Box 1056
Marblehead, MA 01945
USA
Marblehead, MA 01945
USA
Phone
Website
Email Address
Overview
Allievex, a clinical-stage biotechnology company founded by Pappas Capital, is developing novel therapies for the treatment of rare pediatric neurodegenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Mathers
VP - R & D
Eric Zanelli
Browse more venture capital transactions:
Prev: 10/24/2019: Bizly venture capital transaction
Next: 10/24/2019: Winnie venture capital transaction
Share this article
News on VC Transactions
We do our best to report on funding rounds that are announced publicly. All VC database entries on this site are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs